Ignite Creation Date:
2025-12-25 @ 1:47 AM
Ignite Modification Date:
2026-01-06 @ 5:48 AM
Study NCT ID:
NCT03535194
Status:
COMPLETED
Last Update Posted:
2021-03-30
First Post:
2018-05-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-26
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-06-03
Completion Date Type:
ACTUAL
First Submit Date:
2018-05-14
First Submit QC Date:
None
Study First Post Date:
2018-05-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-03-03
Results First Submit QC Date:
None
Results First Post Date:
2021-03-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-03
Last Update Post Date:
2021-03-30
Last Update Post Date Type:
ACTUAL